Data to be Presented at ACG 2015 Annual Meeting in Honolulu, HI on Potential Benefits for EnteraGam® (Serum-derived bovine immunoglobulin/protein isolate, SBI)
FOR IMMEDIATE RELEASE
Entera Health, Inc. today announced a Product Theater and nine poster presentations that will take place at the ACG 2015 Annual Meeting in Honolulu, HI, from Friday, October 16 to Wednesday, October 21, 2015.
ACG 2015 Product Theater
"Management of Gut Barrier Dysfunction in Inflammatory Bowel Disease" Monday, October 19 (9:45 AM – 10:25 AM)
Location: Hawaii Convention Center, ACG Exhibit Hall, Booth #302
To learn more, please visit Entera Health at Booth #616.
Sunday, October 18, 2015 (2:30 PM – 4:30 PM)
Poster ID: #436
Management of Cognitive Function and Asterixis in Seven Cirrhotic Patients with Hepatic Encephalopathy Using Serum Bovine Immunoglobulin/Protein Isolate. Fred C. Fowler, MD, Carolina Digestive Health, Charlotte, NC, USA
Poster ID: #1018
Use of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) for the Management of DMARD-Induced Chronic Loose and Frequent Stools. Mitchel Mah’moud, MD, Duke University School of Medicine, Durham, NC, USA
Poster ID: #756
Serum-Derived Bovine Immunoglobulin/Protein Isolate for the Management of Diarrhea Associated with Chronic Pancreatitis and Pancreatic Insufficiency: A Novel Approach. Raouf Hilal, MD, University of Central Florida College of Medicine Orlando, FL, USA
Poster ID: #627
Nutritional Management of Celiac Disease using Serum-derived Bovine Immunoglobulin/Protein Isolate in a Patient with Poor Gluten-Free Diet Compliance. Larry Good, MD, South Nassau Communities Hospital, Oceanside, NY, USA
Monday, October 19, 2015 (11:40 AM – 12:40 PM)
Poster ID: #P1343
Management of Celiac Disease and Non-Celiac Gluten Sensitivity with Serum-Derived Bovine Immunoglobulin/Protein Isolate. Satish Iduru, MD, GI Specialists of Houston, Houston, TX, USA
Poster ID: #P806
Clinical Management of Lymphocytic Colitis with Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI).
Christine Frissora, MD, The Division of Gastroenterology & Hepatology, Weill Cornell Medical College, Cornell University, New York, NY, USA
Poster ID: #842
Management of Severe Watery Stools with Fecal Incontinence in Ileorectal Anastomosis Patient with Serum-Derived Bovine Immunoglobulin Therapy. Larry Good, MD, South Nassau Communities Hospital, Oceanside, NY, USA
Tuesday, October 20, 2015 (11:00 AM – 12:00 PM)
Poster ID: #1483
Clinical Management of Mastocytic Enterocolitis with Serum-Derived Bovine Immunoglobulin/Protein Isolate. Jason Roy, MSN, ARNP, Central Florida Gastroenterology, Orlando, FL, USA
Poster ID: #1731
Management of Antibiotic-Associated Diarrhea after C. difficile infection with a Serum-Derived Immunoglobulin Preparation. Michael LeVine, MD, Atlanta Gastroenterology Associates, Atlanta, GA, USA
EnteraGam® is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV-associated enteropathy]. EnteraGam® is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam® is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit the product website at http://enteragam.com.
Important Safety Information
EnteraGam® is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam®. Therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant women or nursing mothers. The choice to administer EnteraGam® in pregnant women or nursing mothers is at the clinical discretion of the physician. Medical foods like EnteraGam® are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.
About Entera Health, Inc.
Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. The staff's passion is to help people thrive through healthier living. The staff's motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Learn more at http://www.enterahealth.com/.